When to Suspect H. pylori Infection
Suspect H. pylori infection in patients with active peptic ulcer disease, documented history of ulcers, gastric MALT lymphoma, unexplained iron deficiency anemia, or persistent dyspeptic symptoms, particularly in those under 60 years without alarm features. 1
Primary Clinical Indications for Testing
Strong Indications (Test These Patients)
- Active peptic ulcer disease or documented ulcer history - This represents the highest-yield scenario for H. pylori testing 2, 3
- Gastric MALT lymphoma - H. pylori is causally linked and eradication is therapeutic 2, 1
- Unexplained iron deficiency anemia - Even without gastrointestinal symptoms 1
- History of early gastric cancer resection - For secondary prevention 2
- Chronic dyspeptic symptoms in young patients (<60 years) without alarm features - The "test-and-treat" strategy applies here 4, 2
Consider Testing In
- First-degree relatives of gastric cancer patients - Increased familial risk warrants screening 3, 1
- Patients with persistent dyspepsia despite empiric therapy 2
- Long-term NSAID users before initiating therapy - To reduce ulcer risk 2
- Patients from high-prevalence populations with dyspeptic symptoms 5, 6
When NOT to Test
Critical caveat: Only test if you intend to treat. Testing asymptomatic individuals is not recommended unless they have specific risk factors like family history of gastric cancer 3, 7. The infection is highly prevalent (affecting up to half the global population) but most infected individuals remain asymptomatic 5.
Age Considerations
For patients over 45-60 years presenting with new dyspeptic symptoms or alarm features (weight loss, dysphagia, bleeding, anemia, persistent vomiting), proceed directly to endoscopy rather than non-invasive testing 8, 6. This age threshold reflects increased gastric cancer risk and the need for direct visualization.
Pre-Test Probability Matters
The utility of testing depends heavily on pre-test probability. Testing is most useful when pre-test probability falls between 20-90% 9. Outside this range:
- Below 20% prevalence: Positive results are unreliable (high false-positive rate)
- Above 80% prevalence: Negative results are unreliable (high false-negative rate)
In very high-prevalence populations with strong clinical suspicion, consider empiric treatment without testing 9.
Important Testing Pitfalls
Medication Interference
Stop PPIs for 2 weeks before testing with urea breath test, stool antigen test, rapid urease test, histology, or culture 10, 4. PPIs decrease bacterial load and cause 10-40% false-negative rates. If stopping PPIs is not feasible, use validated IgG serology instead 10.
- H2-receptor antagonists do not require discontinuation 10
- Antibiotics and bismuth must also be stopped 2 weeks prior 4
- A positive test despite PPI use can be trusted - these medications cause false negatives, not false positives 4
Serology Limitations
Serology remains positive long after eradication (a "serologic scar") and should not be used to confirm active infection or assess eradication success 4. Use serology only when:
- Very high pre-test probability exists (e.g., active duodenal ulcer)
- Patient cannot stop PPIs
- Confirm positive serology with breath or stool test before treating 4
Clinical Presentation Clues
While H. pylori causes chronic gastritis universally in infected individuals, suspect it particularly when patients present with:
- Epigastric pain relieved by food or antacids (classic ulcer pattern)
- Recurrent or refractory dyspepsia despite acid suppression
- Unexplained microcytic anemia without obvious bleeding source
- Family history creating heightened concern about gastric cancer risk 3
The infection is typically acquired in childhood and persists lifelong if untreated, so chronic or recurrent symptoms in adults warrant consideration 5.